

Date of Birth: 26th May, 1985
Place of Birth: Shiraz
Marital Status: Married
Business Address: College of Pharmacy, Rady Faculty of Health Sciences
University of Manitoba, 750 McDermot Avenue, Winnipeg, MB,
Canada R3E 0T5
Phone: +1 204 474 9306
Cell phone: +1 204 915 6812
Email: Payam.Peymani@umanitoba.ca
LinkedIn: <https://www.linkedin.com/in/payam-peymani-93b34782/>

EDUCATION

02.2012-03.2016 PhD, Clinical Pharmacology (Pharmacoepidemiology), Shiraz University of Medical Sciences, Shiraz, Iran.

-Average Grade of PhD: A+ (18.70 Out of 20).

-PhD Thesis Title: Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study.

-Thesis Grade: A+ + (19.80 Out of 20)

-Supervisors: Dr Saeid Ghavami and Professor Kamran Bagheri Lankarani.

09.2003- 02.2010 Pharm.D. (Doctor of Pharmacy), Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

-Average Grade of Pharm.D: A (16.70 Out of 20).

-Pharm.D Thesis Title: Evaluation of the Cytotoxic Activity of Novel Multicyclic Compounds Containing Pyridine Ring.

-Thesis Grade: A++ (19.35 Out of 20)

-Supervisors: Professor Ramin Miri and Professor Omidreza Firuzi.

ACADEMIC QUALIFICATIONS AND APPOINTMENTS

06. 2021-Present Postdoctoral Fellow Researcher, College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

- Full Time, Teaching Assistant of Pharmacy courses, Main and Co-Investigator of Pharmacology and Pharmacoepidemiology projects: Design project, writing proposal and protocol, Data Analysis, Documentation and preparing manuscripts.

03. 2021-03.2022 Substitute Member of European Cooperation in Science and Technology (COST Action), CA17112-Prospective European Drug-induced Liver Injury Network), the Netherlands, (<https://proeurodilinet.eu>).

07. 2020-05.2021 Postdoctoral Researcher, Department of Epidemiology, Erasmus University Medical Center Rotterdam, The Netherlands.

-Full Time, Main Investigator of Pharmacoepidemiology projects: Design project, Writing proposal and protocol, Data Analysis, Documentation and preparing manuscripts.

07.2019-06.2020 Postdoctoral Fellowship/ Visiting Scholar, Pharmacoepidemiology and Pharmacovigilance, Department of Clinical Pharmacology & Toxicology, University Hospital Zürich, Zürich, Switzerland.

-Full Time, Main Investigator of Pharmacoepidemiology projects: Design project, writing proposal and protocol, Data Analysis, Documentation and preparing manuscripts.

06.2018-06.2018 Visiting Researcher, Pharmacoepidemiology Group, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.

- 02.2017-11.2020** Assistant Professor and Director, Pharmacoepidemiology and Pharmacoeconomics group, Shiraz University of Medical Sciences, Shiraz, Iran.
- Full Time, Teaching Pharmacy, Pharmaceutical Sciences, Epidemiology and Pharmacoepidemiology Courses to Pharmacy-Medical and PhD Students. Main Investigator of projects, Design projects, writing proposal and protocol, Data Extraction and Analysis, Documentation and preparing manuscripts, Lead Students and his group. Collaboration with Pharmaceutical company for Pharmacoepidemiology and Drug Safety projects.
- 04.2016-01.2017** Postdoctoral Research Fellow, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Full Time, Teaching to Pharmacy and Medical Students, Conduct Pharmacoepidemiology and Public Health Pharmacy Projects.
- 05.2010-01.2012** Pharmaceutical Sciences Researcher, Shiraz University of Medical Sciences, Shiraz, Iran.
-Full Time, Teaching pharmacy related courses to Pharmacy and Medical Students, Design project, writing proposal and protocol, Data Extraction and Analysis, Documentation and preparing manuscripts in the fields of Pharmaceutical Policy and Pharmacoepidemiology.
- 05.2010-01.2014** Community Pharmacist, Community Pharmacies in Shiraz City, South of Iran
-Full Time, Advising-consulting, dispensing, Check Prescriptions, etc...

INTERNATIONAL PROFESSIONAL EXPERIENCES

- 09.2016-Ongoing** Shiraz/Tehran/Isfahan University of Medical Sciences and Iranian Pharmaceutical Companies
- 07.2020-Present** Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands.
- 01.2020-11.2020** D. Department of Human Anatomy and Cell Science, University of Manitoba, Canada.
- 07.2019-06.2020** Department of Clinical Pharmacology & Toxicology, University Hospital Zürich, Switzerland
- 05.2019-Present** C. Department of Pharmacy, Faculty of Medicine, University of Tartu, Tartu, Estonia.

ACQUISITIONS AND GRANT APPLICATIONS

- 2020-Present** Predictors of switching from metformin to Insulin and Pharmacogenetics study on Diabetic patients (Population Based Study)/Rotterdam study, Funded by Erasmus MC (Rotterdam, the Netherlands).
Principal Investigator.
- 2019-2020** Post marketing surveillance of liver injury caused by drugs, Funded by University of Zurich, Switzerland.
Principal Investigator.
Funding Sources: University of Zurich, Exchange and Research Scholarship.
Total Funding: 30,000 (Swiss franc).
- 2019-2020** Pharmacovigilance of MS Medication, Funded by Shiraz University of Medical Sciences, Iran.
Principal Investigator.
Funding Sources, Shiraz University of Medical Sciences, Research Grant/ Young Researcher Grant
Total Funding: 7,500 (Canadian dollar) = 250,000,000 (Iranian rial)

- 2017-2019** Essential cardiovascular and Essential Hypoglycemic (Anti Diabetes) medicine list compilation in Iran health system, Funded by National Grant from FDA of Iran.
Principal Investigator.
Funding Sources: National Grant of FDA of Iran.
Total Funding: 6,000 (Canadian dollar) = 200,000,000 (Iranian rial).
- 2016-2018** Evaluation of accessibility and variety of medications available to Shiraz community (households) in Shiraz: A Population-Based Study.
Principal Investigator.
Funding Sources: Shiraz University of Medical Sciences, University Research Grant
Total Funding: 9,000 (Canadian dollar) = 300,000,000 (Iranian rial)
- 2016-2018** Measuring medicine prices, availability, affordability and price components Hypoglycemic (Anti Diabetes) and cardiovascular medicine,
Principal Investigator.
Funding Sources: National Grant of FDA of Iran.
Total Funding - 15,000 (Canadian dollar) = 500,000,000 (Iranian rial)
- 2020-Present** PARSIAN-Fasa (Non-Communicable Disease) Cohort, Pharmacoepidemiology Evaluation, Funded by Fasa University of Medical Sciences, *Co-investigator*.
- 2020-2020** The effect of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and statins on COVID-19 infection complications and prognosis: a retrospective study COVID-19, Funded by University of Manitoba, Canada and Shiraz University of Medical Sciences, Iran, *Co-investigator*.
- 2020-2020** Assessment of effect of Levamisole on pneumonia caused by COVID-19, Funded by Shiraz University of Medical Sciences, Iran, *Co-investigator*.
- 2019-Present** Mashhad Cardiovascular Cohort, Pharmacoepidemiology Evaluation, Funded by Mashhad University of Medical Sciences, *Co-investigator*.
- 2019-Present** PARSIAN-Kherameh (Non-Communicable Disease) Cohort, Pharmacoepidemiology Evaluation, Funded by Shiraz University of Medical Sciences, *Co-investigator*.
- 2017-2018** Evaluation of International Indicators of patients care in Shiraz Pharmacy Store, Funded by Shiraz University of Medical Sciences, *Principal Investigator*.
- 2014-2016** The therapeutic effect of Midodrine in patients with refractory gastro esophageal reflux disease: a randomized double-blind clinical trial, Funded by Shiraz University of Medical Sciences, Iran, *Co-investigator*.
- 2014-2016** Effect of Octreotide in control of nonvariceal upper GI bleeding: Randomized control trial: randomized double-blind controlled trial. Funded by Shiraz University of Medical Sciences, Iran, *Co-investigator*.
- 2012-2014** Chloroquine Therapy for Non-Responsive HCV Patients Genotype, Funded by Manitoba University, Canada and Shiraz University of Medical Sciences, Iran, *Co-investigator*.

PUBLICATIONS/ PEER-REVIEWED ARTICLES

Total Publications: 45	h-Index	Number of Citations	Source of Citation Data
	15	729	Scopus
	17	1089	Google Scholar
Publication (PubMed)	www.ncbi.nlm.nih.gov/pubmed/?term=payam+peymani		
Publication (Scops)	www.scopus.com/authid/detail.uri?authorId=35269952500		

- Walid Shouman, Joseph A Delaney, Kaarina Kowalec, Marcus Ng, Chelsea Ruth, Jamieson Falk, Christine Leong, Silvia Alessi-Severini, Alekhya Lavu, Payam Peymani, Sherif Eltonsy. Trends of Utilization of Antiepileptic Drugs among Pregnant Women in Manitoba, Canada: A 20-year population-based study, *Frontier Pharmacology*, April 2022 | Volume 13 | Article 871136.
- Saba Afifi, Amir Hossein Alizadeh Bahmani, Leila Zarei, Motahareh Mahi-Birjand, Mehdi Hoorang, Marziyeh Zare, Iman Karimzadeh, Farzad Peirazian, Mahtab Mirjalili, Ali Mohammad Sabzghabae, **Payam Peymani**. Performance of Community Pharmacies by Measuring Responsiveness to Nonmedical Needs: An Application of World Health Organization Responsiveness Framework. *J Res Pharm Pract* . 2021 Aug 3;10(2):59-64. (Corresponding Author).
- Marziyeh Zare, Saba Afifi, Amir Hossein Alizadeh Bahmani, Iman Karimzadeh, Mohammad Salehi-Marzijarani, Leila Zarei, Behnam Honarvar, Sulmaz Ghahremani, Kamran B. Lankarani, Ali Mohammad Sabzghabae, **Payam Peymani**, The Pattern of Medication Usage in the Southern Region of Iran: A Population-Based Study. *J Res Pharm Pract* . 2021 Aug 3;10(2):83-89. (Corresponding Author).
- Tuula, Rutkovska Ieva, Poplavska Elita, Trečiokienė Indre, Merks Piotr, Waszyk-Nowaczyk Magdalena, Drozd Mariola, Tatarević Alena, Radovanlija Maja, Pacadi Carmen, Meštrović Arijana, Viola Réka, Soós Gyöngyvér, Rais Cristina, Táerel Adriana-Elena, Kuželová Magdalena, Zare Marziyeh, **Peymani Payam**. Factors facilitating and hindering development of a Medication Use Review service in Eastern Europe and Iran; cross-sectional exploratory study, *Healthcare (Basel)*. 2021 Sep 14;9(9):1207.
- Imke Ortland, Mahtabasadat Mirjalili, Gerd A Kullak-Ublick, **Payam Peymani**. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database Vigibase from 2010 to 2020, *Swiss Med Wkly*. 2021 May 12;151: w20503 (Senior Author).
- Statins in Patients with COVID-19: A Retrospective Cohort Study in Iranian COVID-19 Patients. **Payam Peymani**, Tania Dehesh, Farnaz Aligolighasemabadi, Mohammadamin Sadeghdoust, Katarzyna Kots, Mazaher Ahmadi, Parvaneh Mehrbod, Pooya Iranpour, Sanaz Dastghaib, Ahmad Nasimian, Amir Ravandi, Naseer Ahmed, Pawan Sharma, Shahla Shojaei, Kamran Bagheri Lankarani, Andrzej Madej, Nima Rezaei, Tayyebeh Madrakian, Marek Los, Hagar Ibrahim, Pooneh Mokarram, Saeid Ghavami. *Translational Medicine Communications*, (2021) 6:3 <https://doi.org/10.1186/s41231-021-00082-5> (First Author).
- Pezeshgi, A, Mubarak, M, Djamali, A, Mostafavi, L, Moghadam-Kia, S, Alimohammadi, N, **Peymani, P.** and Pezeshgi, S, 2021-04-01, COVID-19-associated glomerulopathy and high-risk apol1 genotype; basis for a two-hit mechanism of injury? A narrative review on recent findings, *J Nephropathol*. 2021;10(2): e11.
- Amir Hossein Alizadeh Bahmani, Mehdi Hoorang, Sheida Hosseini, Mehrnoosh Eskandari, Kiana Shayestehfard, Mahyar Shekoohi, Nazafarin Hatami-Mazinani, Saba Afifi, Ali Mohammad Sabzghabae and **Payam Peymani**. Pharmacological and non-pharmacological Studies (Interventional/Non-Interventional Studies) on Coronavirus Disease 2019 (COVID-19). *J Res Pharm Pract* 2020; 9:175-80.

10. Marziyeh Zare, Saba Afifi, Iman Karimzadeh, Mohammad Salehi-Marzijarani, Leila Zarei, Behnam Honarvar, Sulmaz Ghahremani, Kamran B Lankarani, Ali Mohammad Sabzghabae, Fariba Ahmadizar and **Payam Peymani**. A survey on the pattern of medication usage amongst the migrant population residing in southern Iran: Population Based Study. Accepted, 12, 2020, Shiraz E-Med J. (Corresponding Author).
11. Marzieh Zare, Saba Afifi, Iman Karimzadeh, Mustafa Ghaemini, Farzad Peiravian, Mohammad Salehi-Marzijarani, Kamran B Lankarani, Fariba Ahmadizar and **Payam Peymani**. Evaluation of Pharmacist's patient care Process (PPCP) Indicators in Shiraz Community Pharmacies using a newly-validated questioner. Acta Bio-medica: Atenei Parmensis, 07 Sep 2020, 91(3): e2020059. (Corresponding Author).
12. Motahareh mahi birjand, sajad yaghoubi, Mehdi abdollahpour alitappeh, Zahra keshtkaran, Nader Bagheri, aliyar pirouzi, Mehrdad Khatami, koushan sineh sepehr, Iman Karimzadeh, **Payam Peymani**. Protective effect of pharmacological agents against aminoglycoside induced nephrology: a systematic review. Expert Opin Drug Saf. 2020 Feb;19(2):167-186. doi:
13. Fakher S, **Peymani P**, Ghavami S, Mokarram P. The Role of Autophagy in Respiratory Complications of COVID-19, Shiraz E-Med J. Shiraz E-Med J. 2020; 21(6):e102967.
14. Mohaddeseh Hedayati Goudarzi, Nastaran Eizadi-Mood, Marjan Mansourian, Soroush Mohammadi, **Payam Peymani**, Ali Mohammad Sabzghabae. Pediatric Toxicoepidemiology of Tramadol Intoxication in Iran: A 5-year Cross-Sectional Study. J Res Pharm Pract. 2020 Jan-Mar; 9(1): 44–49.
15. Leila Zarei, Iman Karimzadeh, Najmeh Moradi, **Payam Peymani**, Sara Sadi, Zaheer-Ud-Din Babar. Affordability assessment from a static to dynamic concept: scenario-based assessment of Cardiovascular Medicines. Int. J. Environ. Res. Public Health 2020, 17, 1710.
16. Marziyeh Zare, Saba Afifi, Iman Karimzadeh, Mohammad Salehi-Marzijarani, Leila Zarei, Gholamreza Ghazipour, Mahtabalsadat Mirjalili, Kamran B. Lankarani, Ali Mohammad Sabzghabae, Fariba Ahmadizar, **Payam Peymani**. A population-based study on patients complaining regarding community pharmacies services. J Res Pharm Pract 2020; 9:88-93. (Corresponding Author).
17. Bagheri Lankarani K, Sivandzadeh GR, Zare M, Nejati M, Niknam R, Taghavi AR, Ejtehad F, Naini MA, Moini M, Anbardar MH, **Peymani P**. A preliminary report on the use of Midodrine in treating refractory gastroesophageal disease: Randomized Double-Blind Controlled Trial: Midodrine and refractory gastroesophageal disease. Acta Bio Med [Internet]. 2020Feb.7 [cited 2020Feb.8];91(1). (Corresponding Author).
18. Abrishami M, **Peymani P**, Zare M, Lankarani KB. The effect of octreotide in acute nonvariceal upper gastrointestinal bleeding: A randomized, double-blind, placebo-controlled trial. J Res Pharm Pract 2020; 9:94-100.
19. Khatereh Jafarian, Zahra Allameh, Mehrdad Memarzadeh, Ali Saffaei, **Payam Peymani**, Ali Mohammad Sabzghabae. The Responsibility of Clinical Pharmacists for the Safety of Medication Use in Hospitalized Children: A Middle Eastern Experience. J Res Pharm Pract 2019;8:83-91.
20. Hossein Minaei; Mohammad Peikanpourorcid; Nazila yousefiorcid; **Payam Peymani**; Farzad Peiravian; Nikta Shobeiri; Zahra Karimi Majid; Javad Shamsae. Country Pharmaceutical Situation on Access, Quality, and Rational Use of Medicines: An Evidence from a middle-income country. Articles in Press, Accepted Manuscript, Available Online from 21 October 2019. The Iranian Journal of Pharmaceutical Research (IJPR).

21. Maryam Akbari, Kamran B. Lankarani, Reza Tabrizi, Majid Ghayour-Mobarhan, *Payam Peymani*, Gordon Ferns, Amir Ghaderi, and Zatollah Asemi. The Effects of Curcumin on Weight Loss among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Front. Pharmacol*, 12 June 2019 | <https://doi.org/10.3389/fphar.2019.00649>.
22. Reza Tabrizi & Vahidreza Ostadmohammadi & Maryam Akbari & Kamran B. Lankarani & Sina Vakili & *Payam Peymani* & Maryam Karamali & Fariba Kollahdooz & Zatollah Asemi. The Effects of Probiotic Supplementation on Clinical Symptom, Weight Loss, Glycemic Control, Lipid and Hormonal Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. *Probiotics and Antimicrobial Proteins*, <https://doi.org/10.1007/s12602-019-09559-0>.
23. Mohammad Salehi-Marzijarani, Seyed-Mohammad-Taghi Ayatollah1, Saeedeh Pourahmad, Marziyeh Zare., *Payam Peymani*. Network Clustering and Bibliometrics of Pharmacology and Pharmacy Research Outputs Published by Iranian Authors. *Journal of Research in Pharmacy Practice*. *J Res Pharm Pract*. Jan-Mar 2019;8(1):13-19. doi: 10.4103/jrpp.JRPP_18_106.
24. Reza Tabrizi, Omid Reza Tamtaji, Naghmeh Mirhosseini, Kamran B Lankarani, Maryam Akbari, Ehsan Dadgostar, Afshin Borhani-Haghighi, *Payam Peymani*, Fariba Ahmadizar, Zatollah Asemi. The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. *Journal: Pharmacological Research*. Volume 141, March 2019, Pages 85-103.
25. Reza Tabrizi, Omid Reza Tamtaji, Kamran B Lankarani, Naghmeh Mirhosseini, Maryam Akbari, Ehsan Dadgostar, *Payam Peymani* and Zatollah Asemi . The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. The article was first published on 25 Oct 2018, *Food Funct.*, 2018:<http://dx.doi.org/10.1039/C8FO01259H>
26. Nastaran Eizadi-Mood, Raana Ahmadi, Sara Babazadeh, Ahmad Yaraghi, Massoumeh Sadeghi, *Payam Peymani*, Ali Mohammad Sabzghabae. Anemia, depression, and suicidal attempts in women: Is there a relationship? *Journal of Research in Pharmacy Practice*, Year : 2018 | Volume : 7 | Issue : 3 | Page : 136-140
27. Reza Tabrizi; Vahidreza Ostadmohammadi; Kamran B Lankarani; *Payam Peymani*; Maryam Akbari; Fariba Kollahdooz; Zatollah Asemi. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. *Lipids in Health and Disease* (2018) 17:123.
28. Iman Mashhadi, Zahra Kavousi, *Payam Peymani*, Shokrollah Salman Zadeh Ramhormozi, Khosro Keshavarz. Calculation of economic burden of scorpion sting and snake bite from a social perspective in Iran. *Shiraz E-Medical Journal*, in press, 2017.
29. Kavous Eshraghian, Kamran B. Lankarani, Mohammad Reza Fattahi, Atefeh Esmailnejad, *Payam Peymani*. Low Prevalence of Insulin Resistance among Iranian Patients with Chronic Hepatitis C Virus Infection: A Case-Control Study, E-pub Abstract Ahead of Print, *Current Diabetes Reviews*. (Corresponding Author).

30. **Payam Peymani**, Behzad Yeganeh, Siamak Sabour, Bita Geramizadeh, Mohammad Reza Fattahi, Hossein Keyvani, Negar Azarpira, Kevin M Coombs, Saeid Ghavami, PhD, Kamran Bagheri Lankarani. New use of an old drug: Chloroquine reduces viral and ALT levels in HCV non-responders (A randomized, triple-blind, placebo-controlled pilot trial- NCT02058173). Canadian Journal of Physiology and Pharmacology, Can J Physiol Pharmacol. 2016 Jun;94(6):613-9. (First Author).
31. Behzad Yeganeh, Adel Rezaei Moghadam, Javad Alizadeh, Emilia Wiechec, Seyed Moayed Alavian, Mohammad Hashemi, Bita Geramizadeh, Afshin Samali, Kamran Bagheri Lankarani, Martin Post, **Payam Peymani**, Kevin M Coombs, Saeid Ghavami. Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. World J Gastroenterol. 2015 Dec 21;21(47):13225-39. (Co-Corresponding Author).
32. **Payam Peymani**, Saied Ghavami, Behzad Yeganeh, Reza Tabrizi, Siamak Sabour, Bita Geramizadeh, Mohammad Reza Fattahi, Kamran B Lankarani. Clinical and Biochemical Parameters in Non-Response Chronic Hepatitis C Virus Infection Patients Treated With Chloroquine: Pilot Clinical Trial. Acta Biomed 2016; Vol. 87, N. 1: 46-53 (First Author).
33. **Payam Peymani**, Reza Tabrizi, Saba Afifi, Soha Namazi, Seyed Taghi Heydari, Mohammad Khabaz Shirazi, Hasti Nouraei, Elham Sadeghi, Kamran B Lankarani, Najmeh Maharlouei. Knowledge, attitude and practice of general practitioners towards adverse drug reaction (ADR) reporting in Shiraz, Iran. Int J Risk Saf Med. 2016 Mar 16;28(1):25-31 (First Author).
34. Kamran B Lankarani, **Payam Peymani**, Sahar Zare, Reza Tabrizi, MH Kazemi, G.R. Omrani. Prevalence of Vitamin B12 and Folate Deficiencies & Homocysteinemia in Senior Population of Shiraz in South of Iran Tropical Journal of Pharmaceutical Research October 2015; 14(10): 1319-1326. (Corresponding Author).
35. Siamak Sabour, Fatemeh Farzaneh, **Payam Peymani**. Evaluation of the sensitivity and reliability of primary rainbow trout hepatocyte vitellogenin expression as a screening assay for estrogen mimics: Methodological issues. Aquat Toxicol. 2015 Jul;164:175-6. doi: 10.1016/j.aquatox.2015.05.003. <https://pubmed.ncbi.nlm.nih.gov/26004009/>
36. Saba Afifi, Najmeh Maharlouei, **Payam Peymani**, Soha Namazi, Alireza Gholami Gharaei, Pegah Jahani, Kamran B Lankarani. Adverse drug reactions reporting: pharmacists' knowledge, attitude and practice in Shiraz, Iran. The International Journal of Risk & Safety in Medicine. 2014 Jan 1;26(3):139-45.
37. Ali Akbar Shayesteh, Kamran B Lankarani, Seyed Ali Malek-Hosseini, **Payam Peymani**. Single Dose of G-CSF in Leukopenia after Post Liver Transplant. Asian Journal of Pharmaceutical and Clinical Research 2014; 7: 47-49.
38. Kamran B. Lankarani, Mojtaba Mahmoodi, Mehrzad Lotfi, Nima Zamiri, Seyed Taghi Heydari, Fariborz Ghaffarpassand, Mohammad Kazem Fallahzadeh, Meisam Babaeinejad, Najmeh Maharlouei, Omid Mirzaee, Bita Geramizadeh and **Payam Peymani**. Common Carotid Intima-media Thickness in Patients with Non-alcoholic Fatty Liver Disease: A Population-based Case-control Study. Korean J Gastroenterol. 2013 Dec;62(6):344-51.
39. Mohsen Moghadami, Hossein Ruzbahani, Parisa Badiiee, Abolhassan Faramarzi, Reza Ruzbahani, **Payam Peymani**, Kamran Bagheri Lankarani. Invasive Fungal Sinusitis in Immunocompromised Patients: A Multicenter, University Hospital Experience in Shiraz. Advances in Infectious Diseases, 2013, 3, 263-268.

40. Seyed Mehdi Ahmadi, Mohammad Reza Mohammadi, Seyed-Ali Mostafavi, Sareh Keshavarzi, Seyed-Mohammad-Ali kooshesh, Hassan Joulaei, Yaser Sarikhani, **Payam Peymani**, Seyed taghi Heidari, Kamran Bagheri Lankarani. Dependence of the Geriatric Depression on Nutritional Status and Anthropometric Indices in Elderly Population. *Iranian Journal of Psychiatry* 2013. 8(2):92-96.
41. Ali A Shayesteh, Nima Zamiri, **Payam Peymani**, Farzad Jassemi Zargani, kamran B Lankarani. A novel management method for Disseminated Intravascular Coagulation like syndrome after a sting of hemiscorpius lepturus: A case Series. *Tropical Biomedicine*, 2011; 28(3): 518–523 .
42. Reza Boostani, Mojtaba Rismanchi, Abbas Khosravani, Lida Rashidi, Samaneh Kouchaki, **Payam Peymani**, B. Sabayan, K. B. Lankarani. Presenting a hybrid method in order to predict the 2009 pandemic influenza A (H1N1). *Advance Computing: An International Journal*, 2012;3(1)31-43.
43. Ramin Miri, Omidreza Firuzi, **Payam Peymani**, Meysam Zamani, Ahmad Reza Mehdi pour, Zahra Heydari, Maryam Masteri Frahani, Abbas Shafiee. Synthesis, Cytotoxicity, and QSAR study of new aza-cyclopenta[b]fluorene-1,9-dione derivatives. *Chemical Biology & Drug Design*. 2012;79:68-75.
44. Miri R., Firuzi O, **Peymani P**, Nazarian Z., Shafiee A. Synthesis and Cytotoxicity Study of New Cyclopenta[b]quinoline-1, 8-dione Derivatives. *Iranian Journal of Pharmaceutical Research*, 2011, 10 (3): 489-496.
45. Payam Dalvand, **Payam Peymani**, Mohsen Khosravi Maharlooei, Mohyeddin Ziaee Saba Afifi. Novel treatment option for diabetes: Chitosan-insulin tablets encapsulated Antiprotease. *Current Topics in Pharmacology*, 2010; 14:1&2, 35-45.
46. Younes Ghasemi, **Payam Peymani**, Saba Afifi. Quantum Dot: Magic Nanoparticle for Imaging, Detection and Targeting. *ACTA BIOMED*, 2009; 80: 156-165.

CONGRESSES AND INVITED PRESENTATIONS

- 2022** Trends of antiseizure medications utilization in pregnant people: population-level data from two Canadian provinces over two decades, COLLEGE OF PHARMACY RESEARCH DAY, College of Pharmacy, University of Manitoba, 06.04.2022
- 2022** **Keynote:** Hospital Pharmacoepidemiology and Drug Induced Liver Injury, 1st Iranian National Pharmacovigilance and Drug Safety Summit, March 6-8, 2022, Iranian FDA, Zanjan, Iran.
- 2021** Real-World Evidence (RWE) for Drug Safety: Toward Pharmacoepidemiology Research and Big Data, 6th Annual Congress of USERN (Universal Scientific Education and Research Network), 10.11.2021, Zanjan, Iran.
- Exploring the possibilities of implementing the Medication Use Review service in Eastern Europe and Iran, 79th International Scientific Conference of the University of Latvia, 29.01.2-21-19.02.2021, Riga, Latvia.
- 2020** **Keynote:** The Importance of Pharmacoepidemiology Studies in Covid-19(CoV-2) Pandemic, “Third Euro-Asian Pharmacoepidemiology Congress 2020 (EAPEC 2020), December 16 - 18, 2020, Isfahan, Iran”.
- Low-dose aspirin use for primary or secondary prevention of cardiovascular diseases in patients with type 2 diabetes. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. VOLUME 29, SUPPLEMENT 3, OCTOBER 2020, Pharmacoepidemiology PDS & Drug Safety.

Factors associated with switching from oral glucose lowering medications to insulin therapy in type 2 diabetes: The Rotterdam study. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Virtual, September 16–17, 2020. VOLUME 29, SUPPLEMENT 3, OCTOBER 2020, Pharmacoepidemiology PDS & Drug Safety.

Medication use review at community pharmacies: an international pilot project. European Drug Utilisation Research Group (EuroDURG) Conference 2020, March 4-7, 2020, Szeged, Hungary.

2019 Iranian Community Pharmacists Medication Review in Patients on Polypharmacy – Evidence for Action (First Report of Middle East Experience). Medication Use Review in the Era of Digital Care, 27–30.11.2019, Narva-Jõesuu, Ida-Virumaa, Estonia.

Keynote: Methodological Options for the Evaluation of Drug-induced liver injury (DILI): Design and Implementation Pharmacovigilance Program for DILI Detection at Hospital Setting, “Second Euro-Asian Pharmacoepidemiology Congress 2019 (EAPEC 2019), 13-15 November 2019, Tehran, Iran”.

Keynote: The Role of Pharmacoepidemiology Research in Post Marketing Surveillance: Hospital Pharmacoepidemiology, “Second Euro-Asian Pharmacoepidemiology Congress 2019 (EAPEC 2019), 13-15 November 2019, Tehran, Iran”.

Affordability of Diabetes Medicine in Iran: Scenario Based Assessment, “Second Euro-Asian Pharmacoepidemiology Congress 2019 (EAPEC 2019), 13-15 November 2019, Tehran, Iran”.

Country Pharmaceutical Situation Based on World Health Organization Indicators: Evidence From an Upper-Middle Income Country, “Second Euro-Asian Pharmacoepidemiology Congress 2019 (EAPEC 2019), 13-15 November 2019, Tehran, Iran”.

The responsibility of clinical pharmacists for the safety of medication use in hospitalized children: A Middle Eastern experience, “Second Euro-Asian Pharmacoepidemiology Congress 2019 (EAPEC 2019), 13-15 November 2019, Tehran, Iran”.

Essential Medicine List for diabetes in health system of Iran, “Second Euro-Asian Pharmacoepidemiology Congress 2019 (EAPEC 2019), 13-15 November 2019, Tehran, Iran”.

A Household Survey on unused medicine in Shiraz, southern of Iran: population based study, “Second Euro-Asian Pharmacoepidemiology Congress 2019 (EAPEC 2019), 13-15 November 2019, Tehran, Iran”.

2018 **Keynote:** Mobile health in Iran needs more research. 2nd International Mobile Health (MHealth) Seminar. February 21 -22 2018, Shiraz. (Poster Presentation- Corresponding Author)

Tele pharmacy: high priority but with low number of research publication. 2nd International Mobile Health (MHealth) Seminar. February 21 -22 2018, Shiraz. (Poster Presentation- Corresponding Author)

Keynote: Social Pharmacy as a social Aspect of Pharmacoepidemiology: Now More Than Ever. International Conference on Pharmacology and Toxicology –October 18-19, 2018 in Dubai, UAE. (Invited and Keynote Speaker).

2017 Effect of Octreotide in control of non-variceal upper GI bleeding: Randomized, double-blind, placebo-controlled trial. 15th Iranian Pharmaceutical Sciences Congress, 17-19 October, 2017, Hamadan University of Medical Sciences, School of Pharmacy, IPSC 2017 (Poster Presentation).

2015 **Keynote:** Role of Pharmacoepidemiology for Drug Discovery and Development (Pre-Clinical Survey, Clinical Trial and Post Marketing Surveillance), 1st International Conference on Novel

Frontiers in Pharmaceutical & Health Sciences (INNOPHARM 1). October 10 -11. 2015, Bhopal, India. (Invited Speaker, Oral Presentation).

Keynote: Pharmacy and mHealth. Shiraz International Mobile Health (MHealth) Seminar. May 17 -18. 2015, Shiraz. (Invited Speaker, Oral Presentation)

Effect of Chloroquine Therapy on Anthropometric Parameters, Vit D3, Ferritin and Biochemistry Parameters at HCV Infection Patients: Pilot Trial. 6th International Tehran Hepatitis Conference - 1st Global Hepatitis Community Meeting, Tehran, Iran, 27-29 May 2015. (Oral Presentation)

Pilot Study with chloroquine for HCV Non-Responder Patients. 6th International Tehran Hepatitis Conference - 1st Global Hepatitis Community Meeting. Tehran, Iran, 27-29 May 2015. (Oral Presentation).

Autoimmune Hepatitis and Apoptosis, Autophagy, Unfolded Protein Response. 6th International Tehran Hepatitis Conference - 1st Global Hepatitis Community Meeting, Tehran, Iran, 27-29 May 2015. (Oral Presentation)

2012 Community pharmacists' (pharmacy doctor)' knowledge, Attitude and Practice regarding adverse drug reaction reporting in south of Iran (Shiraz). 7th Asia Conference on Pharmacoepidemiology, Bangalore, India, 26-28 October 2012 (Poster Presentations)

General Practitioner' (pharmacy doctor)' knowledge, Attitude and Practice regarding adverse drug reaction reporting in south of Iran (Shiraz). 7th Asia Conference on Pharmacoepidemiology, Bangalore, India, 26-28 October 2012 (Poster Presentations)

Iran's experience on reduction of Tran's fatty acid Content in edible oils.3rd Asia pacific Conference on Public health; Translating Evidence into Public Health action, Kuala Lumpur, Malaysia, 14-15th November 2011(Oral Presentations)

Food Health & Safety Symbol in Iran.3rd Asia pacific Conference on Public health; Translating Evidence into Public Health action, Kuala Lumpur, Malaysia, 14-15th November 2011(Oral Presentations)

2010 Synthesis and Cytotoxicity Study of New Cyclopenta[b]quinoline-1, 8-dione Derivatives. 12th Iranian Pharmaceutical Science Congress, Zanjan, Iran, 2-5 August, 2010. (Poster Presentations)
Synthesis, cytotoxicity, and QSAR study of new aza-cyclopenta[b]fluorene-1, 9-dione derivatives. 12th Iranian Pharmaceutical Science Congress, Zanjan, Iran, 2-5 August, 2010. (Poster Presentations)

Trend in Novel Strategies for Oral Insulin Delivery Systems: Enteric-Coated Chitosan-Insulin Tablets Bearing Antiprotease. 2nd International Student Medical Congress Kosice (ISMCK10). Koscic, Slovakia, 21 -24 June 2010. (Oral Presentations in Pharmacology Section)

Treatment of Diabetes Mellitus type1 by Increasing HLA-G Expression with Polymeric Nanoparticles Using mesenchymal stem cells and insulin producing cells (IPC). Fourth (4th) Iranian Controlled Release conference (ICRC2009), Zanjan, Iran, 6-8 Oct 2009. (Poster Presentations)

MENTORING AND CO-SUPERVISION

2019–Ongoing Pediatric Residency's Thesis, Zarsanj N, Faculty of Medicine, Shiraz University of Medical Sciences.
Title: Pharmacoepidemiologic study of drug–drug interactions in onco-hematological pediatric patients.

- 2018–2020** Master’s Thesis of Health Policy, Zare M, Faculty of Medical, Shiraz University of Medical Sciences.
Title: Study of Adverse effects of Synovex, Resigene and ziferone drugs (Iranian medicines for MS therapy) in patients with multiple sclerosis (design and implementation of an adverse drug effect registration system).
- 2017–2019** Pharmacy Doctorate’s Thesis, Jalali N, Faculty of Pharmacy, Shiraz University of Medical Sciences.
Title: Evaluation of Cost Effectiveness of Drug Therapies in Patients with Chronic Hepatitis C with Genotype 1 in Iran.
- 2017-2019** Pharmacy Doctorate’s Thesis, Mostafavipour M, Faculty of Pharmacy, Shiraz University of Medical Sciences.
Title: Evaluation of Everlimus Technology and therapy in Patients with Renal Cell Carcinoma in Comparison with Tacrolimus and Everolimus with Lenvatinib in Iran.

AWARDS

- June 2010** Third Prize in Pharmacology: Trend in Novel Strategies for Oral Insulin Delivery Systems: Enteric-Coated Chitosan-Insulin Tablets Bearing Antiprotease (Oral Presentation): 2nd International Student Medical, Congress Kosice (ISMCK10). Kosice, Slovakia.
- October 2009** Second Prize in Pharmaceutical Sciences: Treatment of Diabetes Mellitus Type 1 by Increasing HLAG Expression with Polymeric Nanoparticles Using Mesenchymal stem cells and insulin producing cells (IPC) (Poster Presentation). Fourth (4th) Iranian Controlled Release Conference (ICRC2009), Zanzjan, Iran
- August 2008** First Prize in Pharmaceutical Biotechnology: Fabrication and Optimization of Chitosan Nanoparticles as a Novel Gene Delivery System for Efficient Transfection of DNA in Cancer Gene Therapy: Tumor suppressor gene therapy for cancer (Poster Presentation). The 11th Iranian Pharmaceutical Sciences Conference (IPSC2008), Kerman, Iran.

TEACHING EXPERIENCE

- 2022-Present** Co-lecturer and teaching assistant, College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba.
Course Title: Pharmacotherapy, Critical Appraisal, Observational Study.
Section: Pharm.D and Pharmacy Undergraduate students.
Number of Students: 35
Number of Credits: 2
Lecture Hours Per Week: 3
Course and lecturer performance evaluated by students. Assessments are available upon request.
- 2018-2021** Course and Curriculum Designer, Main Lecturer and Instructor, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Course Title: Pharmacoepidemiology, Pharmacovigilance, Clinical Trial and Statistics.
Section: Ph.D. Students and Clinical Pharmacy residency students.
Number of Students: 5
Number of Credits: 4
Lecture Hours Per Week: 6
Course and lecturer performance evaluated by students. Assessments are available upon request.
- 2016-2020** Coordinator and Lecturer, Faculty of Medicine, Shiraz University of Medical sciences, Shiraz, Iran
Course Title: Research Methodology, Knowledge Translation and Exchange, Epidemiology
Section: Master of Public Health (MPH) Students

Number of Students: 70
Number of Credits: 3
Lecture Hours Per Week: 4
Course and lecturer performance evaluated by students. Assessments are available upon request.

- 2016-2019** Lecturer and Instructor, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Course Title: Research Methodology and Epidemiology
Section: M.D Students
Number of Students: 50
Number of Credits: 2
Lecture Hours Per Week: 2
Course and lecturer performance evaluated by students. Assessments are available upon request.
- 2017-2019** Lecturer and Instructor, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
Course Title: Research Methodology in Clinical Pharmacology
Section: Pharm.D (Pharmacy Doctorate) Students
Number of Students: 40
Number of Credits: 2
Lecture Hours Per Week: 2
Course and lecturer performance evaluated by students. Assessments are available upon request.
- 2015-2015** Lecturer and Instructor, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
Course Title: Medication Error center for Hospital pharmacist
Section: Pharm.D (Pharmacy Doctorate) Students
Number of Students: 50
Number of Credits: 2
Lecture Hours Per Week: 2
- 2010-2011** Lecturer and Instructor, Vice-chancellor for Educational Affairs, Iranian academic center for Education, Culture and Research
Course Title: Drug Information
Section: Pharm.D (Pharmacy Doctorate) Students
Number of Students: 110
Number of Credits: 2
Lecture Hours Per Week: 2
- 2012-2013** Lecturer and Instructor, Vice-chancellor for Educational Affairs, Iranian academic center for Education, Culture and Research
Course Title: Drug Information
Section: Pharm.D (Pharmacy Doctorate) Students
Number of Students: 110
Number of Credits: 2
Lecture Hours Per Week: 2
- 2011-2012** Lecturer, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
Course Title: Research Methods and Study Design in Pharmaceutical Sciences
Section: Pharm.D (Pharmacy Doctorate) Students
Number of Students: 50
Number of Credits: 1
Lecture Hours Per Week: 1
- 2011-2012** Lecturer, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
Course Title: Drug Discovery and Development

Section: Pharm.D (Pharmacy Doctorate) Students
Number of Students: 50
Number of Credits: 1
Lecture Hours Per Week: 1

2011-2012 Lecturer, Faculty of Pharmacy, Shiraz University of Medical Sciences,
Shiraz, Iran
Course Title: Research Skill Training
Section: Pharm.D (Pharmacy Doctorate) Students
Number of Students: 50
Number of Credits: 1

COURSE AND CURRICULUM DEVELOPMENT

2018 Instructor and Chair, Faculty of pharmacy/Medicine, Shiraz University of Medical Sciences
Course Title: Pharmacoepidemiology.
Course Level: Post Graduate.
For the first time, I Prepared a curriculum/course description for Pharmacoepidemiology courses
in the South of Iran Country.

2018 Instructor and Chair, Faculty of Pharmacy/Medicine, Shiraz University of Medical Sciences
Course Title: Pharmacovigilance and Drug Safety.
Course Level: Post Graduate.
For the first time, I Prepared a curriculum/course description for Pharmacovigilance
courses in the South of Iran Country.

MENTORING ACTIVITIES

2018/10 - 2021 Trainer, Health Policy Research Center
Number of Mentorees: 3
Mentorees: Paria Oskuei, Mahtabsadat Mirjalili and Ehsan Mirzaie
Trainer of Pharm.D-MPH Program Internship course

EXTERNAL AND INTERNAL GRADUATE EXAMINATION BOARDS

2016- 2020 Educational and Thesis Reviewing Board Member, Shiraz University of Medical
Science, Pharm.D-MPH and M.D-MPH Program

WORKSHOPS ATTENDED

09.2021 Sexual Violence Awareness Modules Badge/Certificate, University of Manitoba, Winnipeg
Canada.

09.2021 Accessibly Training (Customer Service) Certificate, University of Manitoba, Winnipeg
Canada.

08.2021 Sex and Gender in the Analysis of Secondary Data from Human Participants, CIHR Institute
of Gender and Health, Canada.

07.2021 Sex and Gender in Primary Data Collection with Human Participants, CIHR Institute of
Gender and Health, Canada.

06.2021 Personal Health Information Act (PHIA), University of Manitoba, Winnipeg, Canada.

06.2021 Manitoba Centre for Health Policy (MCHP) Accreditation,

01.2015 International Workshop of Qualitative Research, Shiraz University of Medical Sciences,
Iran.

- 11. 2014** Knowledge Translation Workshop, Shiraz University of Medical Sciences, Iran and University of Manitoba, Canada.
- 10. 2012** Pharmacoepidemiology Certificate, 7th Asia Conference on Pharmacoepidemiology, Bangalore, India.
- 09.2010** Systematic Review and Meta-Analysis, Shiraz University of Medical Sciences, Shiraz, Iran.
- 10. 2008** Industrial Pharmacy Course, Pasteur Institute, Karaj Production and Research Center Tehran, Iran.

KNOWLEDGE AND TECHNOLOGY TRANSLATION

- 2019/7 - 2024/12**
- Main Researcher, Consulting for Industry
 - Target Stakeholder: Industrial Consortium
 - Outcome / Deliverable: Design and Implementation of drug-induced liver injuries (DILI)Algorithm in hospital
 - Evidence of Uptake/Impact: Due to difficulty in identifying and differentiating DILI from other causes of hepatic injury, this system can really help industries, hospitals and health care staffs. this system will help pharmaceutical industries to detect DILI as soon as possible and reduce burden of DILI, reduce morbidity and mortality.
- 2019/3 - 2020/11**
- Principal Investigator, Policy/Regulation Development
 - Group/Organization/Business Serviced: Shiraz University of Medical Sciences and Iranian Pharmacy Association
 - Target Stakeholder: Healthcare Personnel
 - Outcome / Deliverable: Real Word Evidence on current situation of Clinical Pharmacists activities
 - Evidence of Uptake/Impact: Report Efficacy of current practice and guidelines of Clinical Pharmacists
- 2018/4 - 2019/4**
- Principal Investigator/Organizer, Community Engagement
 - Target Stakeholder: General Public
 - Outcome / Deliverable: Arrange Educational Classes, Teach and Learn About: Adverse drug reaction (ADR), How Define ADR, How- When and Where to Report ADR
 - Evidence of Uptake/Impact: Prepared Policy Brief for Community Centers and Policy Makers
- 2018/1 - 2018/11**
- Principal Investigator, Policy/Regulation Development
 - Group/Organization/Business Serviced: Shiraz University of Medical Sciences and Iranian Pharmacy Association
 - Target Stakeholder: Government Personnel
 - Outcome / Deliverable: Knowledge, attitude and practice of General Practitioners towards adverse drug reaction reporting for Policy Makers and Medical Staff.
 - Evidence of Uptake/Impact: Report Efficacy of current practice and guidelines and How improve current situation

LANGUAGES SKILLS

Persian-Farsi (Native)

English (Fluent), IELTS (Average Score: 6.5), worked 10 years in English-Language Settings

German (Beginner)

EDITORIAL EXPERIENCES

- 2021-Present** Reviewer of the Pharmacoepidemiology and Drug Safety (PDS) Journal.
- 2021-Present** Reviewer of the Canadian Journal of Diabetes (CJD).
- 2015-Present** Reviewer of the PLOS ONE Journal.
- 2014- Present** Reviewer and Associated Editor of the Shiraz Electronic Medical Journal.
- 2014-Present** Reviewer and Associated Editor of the Annals of Colorectal Journal.
- 2010-Present** Editorial Board of Archives of Pharmacy Practice (APP) Journal.

MEMBERSHIP

- 2012-Present** Member of the International Society for Pharmacoepidemiology (ISPE)
- 2014-Present** Member of the Iranian Pharmaceutical Sciences Society
- 2022-Prrsent** Trainee Member, Society for Birth Defects Research and Prevention